Skip to main content
Erschienen in: Lung 5/2007

01.09.2007

Involvement of Mutation-based Inhibition of β-Catenin Phosphorylation at Ser33 in the Malignant Progression of Lung (Pre)neoplastic Lesions Induced by N-nitrosobis(2-hydroxypropyl)amine in Male Fischer 344 Rats

verfasst von: Maki Igarashi, Midori Yoshida, Manabu Watanabe, Toshiyuki Yamada, Takuya Sakurai, Yoshifumi Endo, Nozomi Miyajima, Akihiko Maekawa, Tsuneyuki Oikawa, Sumio Sugano, Dai Nakae

Erschienen in: Lung | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

In this study we investigated the Ser33 phosphorylation status of β-catenin protein in relation to genomic mutations in lung (pre)neoplastic lesions induced by N-nitrosobis(2-hydroxypropyl)amine (BHP) in male Fischer 344 rats. Six-week-old animals received 2000 ppm of BHP in the drinking water for 8 weeks and were sacrificed 12 weeks thereafter. Histopathologically, 69 of 75 rats demonstrated multiple lung (pre)neoplastic lesions, classified into 27 slight and 33 advanced hyperplasias (preneoplasms) and 61 neoplasms, including adenomas, adenocarcinomas, and adenosquamous carcinomas. Nucleotide mutation analysis of the β-catenin gene detected a total of 33 mutations in 12 assessed lung (pre)neoplastic lesions. The mutations tended to accumulate in positions near the phosphorylation region of the gene, between codons 33 and 45. Immunohistochemical analysis showed β-catenin protein expression to be increased and its localization changed from the cell membrane to the cytoplasm and finally the nuclei with advancing malignancy of the lung lesions. In contrast, the expression of phosphorlyated β-catenin protein at Ser33 was weakened in lung (pre)neoplastic lesions compared to normal lung tissues. These results suggest that BHP-induced mutation of the β-catenin gene results in amino acid conversions in its product protein, which in turn lead to inhibition of phosphorylation of the protein and escape from protein degradation. These phenomena might contribute to the malignant progression of the lung (pre)neoplastic lesions, which start from the relatively early stage in lung carcinogenesis.
Literatur
1.
2.
Zurück zum Zitat Imai T, Onose J, Hasumura M, Ueda M, Takizawa T, Hirose M (2004) Sequential analysis of development of invasive thyroid follicular cell carcinomas in inflamed capsular regions of rats treated with sulfadimethoxine after N-bis(2-hydroxypropyl)nitrosamine-initiation. Toxicol Pathol 32:229–236PubMedCrossRef Imai T, Onose J, Hasumura M, Ueda M, Takizawa T, Hirose M (2004) Sequential analysis of development of invasive thyroid follicular cell carcinomas in inflamed capsular regions of rats treated with sulfadimethoxine after N-bis(2-hydroxypropyl)nitrosamine-initiation. Toxicol Pathol 32:229–236PubMedCrossRef
3.
Zurück zum Zitat Yamamoto K, Yokose Y, Nakajima A, Eimoto H, Shiraiwa K, Tamura K, Tsutumi M, Konishi Y (1988) Comparative histochemical investigation of the glutathione S-transferase placental form and gamma-glutamyltranspeptidase during N-nitrosobis(2-hydroxypropyl)amine-induced lung carcinogenesis in rats. Carcinogenesis 9:399–404PubMedCrossRef Yamamoto K, Yokose Y, Nakajima A, Eimoto H, Shiraiwa K, Tamura K, Tsutumi M, Konishi Y (1988) Comparative histochemical investigation of the glutathione S-transferase placental form and gamma-glutamyltranspeptidase during N-nitrosobis(2-hydroxypropyl)amine-induced lung carcinogenesis in rats. Carcinogenesis 9:399–404PubMedCrossRef
4.
Zurück zum Zitat Okamura M, Moto M, Kashida Y, Machida N, Mitsumori K (2004) Carcinogenic susceptibility to N-bis(2-hydroxypropyl)mitrosamine (DHPN) in rasH2 mice. Toxicol Pathol 32:374–481 Okamura M, Moto M, Kashida Y, Machida N, Mitsumori K (2004) Carcinogenic susceptibility to N-bis(2-hydroxypropyl)mitrosamine (DHPN) in rasH2 mice. Toxicol Pathol 32:374–481
5.
Zurück zum Zitat Janne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA Johnson BE (2002) Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95:1528–1538PubMedCrossRef Janne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA Johnson BE (2002) Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95:1528–1538PubMedCrossRef
6.
Zurück zum Zitat Tsujiuchi T, Masutani M, Konishi Y (2003) Molecular aspects during multi-step chemical induced carcinogenesis in the lung and pancreas. J Toxicol Pathol 16:133–138CrossRef Tsujiuchi T, Masutani M, Konishi Y (2003) Molecular aspects during multi-step chemical induced carcinogenesis in the lung and pancreas. J Toxicol Pathol 16:133–138CrossRef
7.
Zurück zum Zitat Tsujiuchi T, Tsutsumi M, Sasaki Y, Murata N, Konishi Y (2000) Mutations of adenomatous polyposis coli and β-catenin genes during progression of lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Cancer Res 60:6611–6616PubMed Tsujiuchi T, Tsutsumi M, Sasaki Y, Murata N, Konishi Y (2000) Mutations of adenomatous polyposis coli and β-catenin genes during progression of lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Cancer Res 60:6611–6616PubMed
8.
Zurück zum Zitat Kato A, Shimizu K, Shimoichi Y, Fujii H, Honoki K, Tsujiuchi T (2006) Aberrant DNA methylation of E-cadherin and p16 genes in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine. Mol Carcinog 45:106–111PubMedCrossRef Kato A, Shimizu K, Shimoichi Y, Fujii H, Honoki K, Tsujiuchi T (2006) Aberrant DNA methylation of E-cadherin and p16 genes in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine. Mol Carcinog 45:106–111PubMedCrossRef
9.
Zurück zum Zitat Shimizu K, Kato A, Shigemura M, Fujii H, Honoki K, Tsujiuchi T (2006) Aberrant methylation patterns of the Rassf1a gene in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine. Mol Carcinog 45:112–117PubMedCrossRef Shimizu K, Kato A, Shigemura M, Fujii H, Honoki K, Tsujiuchi T (2006) Aberrant methylation patterns of the Rassf1a gene in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine. Mol Carcinog 45:112–117PubMedCrossRef
10.
Zurück zum Zitat Ding Y, Dale T (2002) Wnt signal transduction: kinase cogs in a nano-machine? Trends Biochem Sci 27:327–329PubMedCrossRef Ding Y, Dale T (2002) Wnt signal transduction: kinase cogs in a nano-machine? Trends Biochem Sci 27:327–329PubMedCrossRef
11.
Zurück zum Zitat Kikuchi A (2003) Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94:225–229PubMedCrossRef Kikuchi A (2003) Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94:225–229PubMedCrossRef
12.
Zurück zum Zitat Yamada Y, Oyama T, Hirose Y, Hara A, Susie S, Yoshida K, Yoshimi N, Mori H (2003) β-Catenin mutation is selected during malignant transformation in colon carcinogenesis. Carcinogenesis 24:91–97PubMedCrossRef Yamada Y, Oyama T, Hirose Y, Hara A, Susie S, Yoshida K, Yoshimi N, Mori H (2003) β-Catenin mutation is selected during malignant transformation in colon carcinogenesis. Carcinogenesis 24:91–97PubMedCrossRef
13.
Zurück zum Zitat Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068PubMedCrossRef Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068PubMedCrossRef
14.
Zurück zum Zitat Uematsu F, Takahashi M, Yoshida M, Igarashi M, Nakae D (2006) Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci 97:611–617PubMedCrossRef Uematsu F, Takahashi M, Yoshida M, Igarashi M, Nakae D (2006) Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci 97:611–617PubMedCrossRef
15.
Zurück zum Zitat Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158PubMedCrossRef Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158PubMedCrossRef
16.
Zurück zum Zitat Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA (1999) Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155:703–710PubMed Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA (1999) Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155:703–710PubMed
17.
Zurück zum Zitat Blum CA, Tanaka T, Zhong X, Li Q, Dashwood WM, Pereira C, Xu M, Dashwood RH (2003) Mutational analysis of Ctnnb1 and Apc in tumors from rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-f]quinoline: mutational ‘hotspots’ and the relative expression of beta-catenin and c-jun. Mol Carcinog 36:195–203PubMedCrossRef Blum CA, Tanaka T, Zhong X, Li Q, Dashwood WM, Pereira C, Xu M, Dashwood RH (2003) Mutational analysis of Ctnnb1 and Apc in tumors from rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-f]quinoline: mutational ‘hotspots’ and the relative expression of beta-catenin and c-jun. Mol Carcinog 36:195–203PubMedCrossRef
18.
Zurück zum Zitat Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274PubMedCrossRef Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274PubMedCrossRef
19.
Zurück zum Zitat Gandini D, Gogioso L, Bolognesi M, Bordo D (1996) Patterns in ionizable side chain interactions in protein structures. Proteins 24:439–449PubMedCrossRef Gandini D, Gogioso L, Bolognesi M, Bordo D (1996) Patterns in ionizable side chain interactions in protein structures. Proteins 24:439–449PubMedCrossRef
20.
Zurück zum Zitat Megy S, Bertho G, Gharbi-Benarous J, Baleux F, Benarous R, Girault JP (2005) Solution structure of a peptide derived from the oncogenic protein β-catenin in its phosphorylated and nonphosphorylated states. Peptides 26:227–241PubMedCrossRef Megy S, Bertho G, Gharbi-Benarous J, Baleux F, Benarous R, Girault JP (2005) Solution structure of a peptide derived from the oncogenic protein β-catenin in its phosphorylated and nonphosphorylated states. Peptides 26:227–241PubMedCrossRef
Metadaten
Titel
Involvement of Mutation-based Inhibition of β-Catenin Phosphorylation at Ser33 in the Malignant Progression of Lung (Pre)neoplastic Lesions Induced by N-nitrosobis(2-hydroxypropyl)amine in Male Fischer 344 Rats
verfasst von
Maki Igarashi
Midori Yoshida
Manabu Watanabe
Toshiyuki Yamada
Takuya Sakurai
Yoshifumi Endo
Nozomi Miyajima
Akihiko Maekawa
Tsuneyuki Oikawa
Sumio Sugano
Dai Nakae
Publikationsdatum
01.09.2007
Verlag
Springer-Verlag
Erschienen in
Lung / Ausgabe 5/2007
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-007-9017-y

Weitere Artikel der Ausgabe 5/2007

Lung 5/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.